Navigation Links
First Treatment to Directly Target Tumor Blood Supply

For the first time, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City have demonstrated// in patients the ability of an antibody to directly target the blood supply of a wide variety of tumors, leaving healthy tissues unharmed.

The Phase I clinical trial tested an antibody called J591, targeted to the prostate specific membrane antigen (PSMA).

PSMA has been an attractive target for cancer drug development because it is not only present in high amounts in prostate cancers but it also is the only known molecular target present on tumor blood vessels but not normal blood vessels. The ability to target PSMA on blood vessels would provide a way to directly attack a tumor’s blood supply without affecting normal blood vessels.

"Anti-angiogenic" cancer therapies that focus on the tumor's blood supply are not new. However, other such treatments starve tumors of their blood supply indirectly, by reducing blood vessel growth signals. J591 may work in a new way, taking anti-angiogenic therapy to the next level by directly targeting PSMA on the cells of the tumor blood vessels and then zooming in for the kill.

The trial, which appears in the Feb. 10 issue of the Journal of Clinical Oncology, involved 27 cancer patients with a wide range of solid tumors -- including kidney, bladder, lung, breast, colorectal, pancreas and melanoma. All patients had widespread disease that had failed conventional treatments.

"Prior to this trial, we had laboratory data that indicated PSMA was present on tumor but not normal blood vessels," explains the study's senior author, Dr. Neil H. Bander, a urological cancer specialist at NewYork-Presbyterian/Weill Cornell and the Bernard and Josephine Chaus Professor of Urological Oncology at Weill Cornell Medical College. "We hypothesized that we could use an antibody to PSMA to specifically target tumor blood supply. This was a proof-of-principle t rial to confirm -- or reject -- our hypothesis."

The research team used a radioactive tracer, attached to the antibody, to follow J591's progress throughout the body.

"We showed that J591 can directly target the tumor's blood vessels," Dr. Bander says. "That's an important first. It represents the difference between laying siege to a village vs. sending in troops with heavy artillery. Current anti-angiogenic approaches starve the blood vessels of growth signals, but with J591, one directly targets a lethal blow right at the tumor blood supply."

As its name implies, PSMA was first spotted in prostate cancers. However, in 1998, Dr. Bander's team found the antigen to be present in the blood vessels of a wide range of tumor types -- but not healthy vasculature. This finding has been subsequently verified by several research teams.

As expected, the antibody therapy left healthy tissue alone, resulting in very low levels of toxicity for patients. The relatively short, small trial did not turn up significant reductions in tumor volume, but Dr. Bander says the trial wasn't designed to do so.

"This was a proof-of-principle study designed purely to confirm that we could successfully target tumor vasculature without targeting normal tissue," he says. "Now that we have confirmed specific and accurate targeting, in subsequent studies we will arm the J591 antibody with drugs or radioactivity, and then we will assess tumor response. We are already using such armed antibodies in patients with prostate cancer and have been able to show significant anti-tumor activity."

The big news now is that J591, and compounds like it, could someday offer cancer patients a brand new weapon as they fight the disease. But Dr. Bander’s team doesn't expect that cancer patients would rely on PSMA-targeted therapies alone.

"In the future, we envision a multi-pronged attack on the tumor -- for example, combining thera pies aimed directly at the malignant cells, along with therapies to both directly kill the tumor's blood supply as well as prevent it from re-growing," he says.

When it comes to fighting cancer, any new treatment option is always welcome, he adds. "With an antibody to PSMA like J591, we hope to open up a whole new front in the war against this disease."

Source-Newswise
SR
'"/>




Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First Artificial Heart patient has Major setback
5. First head-to-head trials of once weekly Fosamax and Actonel therapies
6. WHO Declares Vietnam First Country to Control SARS
7. Russia Reports First SARS Case
8. Hope for First New Melanoma Treatment in Decades
9. First global SARS meet opens
10. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
11. Hyderabad To Have Asia’s First Catheter Making Uni
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... Knoxville, TN (PRWEB) , ... May 26, 2016 ... ... professional fitness education and products recently hosted the first PowerWave Instructor Certification Course ... Fouts, who lead a group of fitness professional through the 8 hour interactive ...
(Date:5/26/2016)... , ... May 26, 2016 , ... On May 23rd ... Research Water Life Science® and international water advocate, was honored by Ashram, Inc. as ... in ancient Egypt who knelt on the banks of the Nile to fill their ...
(Date:5/26/2016)... Petaluma, Ca (PRWEB) , ... May 26, 2016 ... ... joined the organization to provide strategic sales leadership and to further develop their ... holds a B.S. in Business Administration with a concentration in Marketing and an ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... , ... May 26, 2016 ... ... promoting quality-based imaging practices, is seeking nominations to serve on its Accreditation ... imaging. , “RadSite’s quality-benchmarking activities incorporate key process and outcome ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... May 25, 2016 According to ... Type (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic ... User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to ... Medical Animation Market for the forecast period of 2016 ... 301.3 Million by 2021 from USD 117.3 Million in ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
Breaking Medicine Technology: